Yumi Kang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Yumi Kang has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
Akio Tanaka
Department of Dermatology, Graduate School of Biomedical Sciences, Hiroshima University, Hiroshima, Japan
1 shared publicationAmbrish Singh
Eli Lilly and Company Lilly Bengaluru Bengaluru Karnataka India
1 shared publicationAtushi Otsuka
Department of Dermatology, Kindai University Hospital, Sakai, Japan
1 shared publication- Chie Hashimoto
Japan Drug Development and Medical Affairs, Eli Lilly Japan K.K., Kobe, Japan
1 shared publication - Daisuke Danno
Department of Neurology and Headache Center Tominaga Hospital Osaka Japan
1 shared publication Hitoe Torisu-Itakura
Eli Lilly Japan K.K., Kobe, Hyogo, Japan
1 shared publication
Latest Publications
- Open Access
- 14 July 2026
- Published by Springer Nature in Pain and Therapy
- Vol. 15 (5) , 1401-1432
Characteristics and Treatment Patterns in People with Burden of Migraine: A Subgroup Analysis of the OVERCOME Japan 2nd Study
The burden of migraine on an individual's life is associated with an individual's background. However, limited evidence in Japan exists on the association of age, sex, employment, income, and family caregiving with patient-reported outcomes (PROs) and migraine treatment patterns. This analysis of the ObserVational survey of the Epidemiology, tReatment, and Care Of MigrainE (OVERCOME [Japan]) 2nd study describes the migraine burden and treatment usage of individuals with migraine across these demographic subgroups. Participants self-reported demographic and clinical characteristics, and PRO instrument responses, such as Headache Impact Test-6, Migraine Disability Assessment Scale (MIDAS), Migraine-Specific Quality of Life Questionnaire version 2.1, Migraine Interictal Burden Scale-4 (MIBS-4), and Impact of Migraine on Partners and Adolescent Children Scale. They also reported use of over-the-counter and prescription drugs for migraine, and headache-related expenses. Descriptive statistics were reported according to sex, employment status, menstrual-related migraine status and frequency, annual personal and family income, age, and family caregiving status for the elderly. Female sex, unemployment, presence of menstrual-related migraine, low personal or family income, and family caregiving for elders appeared to increase migraine burden and impact prescription drug use. Specifically, men tended to have higher triptan (11.7% vs. 8.7%) and preventive medication use (18.3% vs. 11.2%) than women; unemployed women had the highest proportion of MIDAS grade IV (14.1%); women with menstrual-related migraine appeared to have greater MIBS-4 severe burden (36.3% vs. 27.8%) than those without; and family caregivers tended to have higher MIBS-4 severe burden (39.2% vs. 26.0%) and prescription drug use than non-caregivers. Respondent sex further appeared to influence migraine burden and treatment patterns within the employment and income subgroups. These data suggest certain sociodemographic groups may suffer from greater migraine burden and have reduced access to effective treatment and care. We hope this study's results will help healthcare providers and societies identify such populations with migraine and address potential clinical care gaps.
- 14 July 2026
- Published by Springer Nature in Pain and Therapy
- Vol. 15 (5) , 1401-1432
Open AccessCharacteristics and Treatment Patterns in People with Burden of Migraine: A Subgroup Analysis of the OVERCOME Japan 2nd Study
The burden of migraine on an individual's life is associated with an individual's background. However, limited evidence in Japan exists on the association of age, sex, employment, income, and family caregiving with patient-reported outcomes (PROs) and migraine treatment patterns. This analysis of the ObserVational survey of the Epidemiology, tReatment, and Care Of MigrainE (OVERCOME [Japan]) 2nd study describes the migraine burden and treatment usage of individuals with migraine across these demographic subgroups. Participants self-reported demographic and clinical characteristics, and PRO instrument responses, such as Headache Impact Test-6, Migraine Disability Assessment Scale (MIDAS), Migraine-Specific Quality of Life Questionnaire version 2.1, Migraine Interictal Burden Scale-4 (MIBS-4), and Impact of Migraine on Partners and Adolescent Children Scale. They also reported use of over-the-counter and prescription drugs for migraine, and headache-related expenses. Descriptive statistics were reported according to sex, employment status, menstrual-related migraine status and frequency, annual personal and family income, age, and family caregiving status for the elderly. Female sex, unemployment, presence of menstrual-related migraine, low personal or family income, and family caregiving for elders appeared to increase migraine burden and impact prescription drug use. Specifically, men tended to have higher triptan (11.7% vs. 8.7%) and preventive medication use (18.3% vs. 11.2%) than women; unemployed women had the highest proportion of MIDAS grade IV (14.1%); women with menstrual-related migraine appeared to have greater MIBS-4 severe burden (36.3% vs. 27.8%) than those without; and family caregivers tended to have higher MIBS-4 severe burden (39.2% vs. 26.0%) and prescription drug use than non-caregivers. Respondent sex further appeared to influence migraine burden and treatment patterns within the employment and income subgroups. These data suggest certain sociodemographic groups may suffer from greater migraine burden and have reduced access to effective treatment and care. We hope this study's results will help healthcare providers and societies identify such populations with migraine and address potential clinical care gaps.
- Open Access
- 18 April 2026
- Published by Springer Nature in Advances in Therapy
- Vol. 43 (7) , 2977-2995
Treatment Patterns and Perceptions of Treatment Options in Japanese Pediatric and Adolescent Patients with Atopic Dermatitis
Atopic dermatitis (AD) is a relapsing, chronic inflammatory skin condition characterized by intense itching and eczematous lesions. AD is common in pediatric patients, but treatment options are limited for these patients and data on treatment patterns are scarce. This study aimed to descriptively evaluate treatments used in pediatric AD and physician- and patient-reported perspectives of available options in real-world practice in Japan. Data were drawn from the Adelphi Real World Pediatric and Adolescent AD Disease Specific Programme™, a cross-sectional survey, with retrospective data collection, of physicians and patients in Japan from July to December 2022. Physicians completed patient record forms for their next 3-10 consecutively consulting patients, collecting data on demographics and clinical characteristics, treatment regimens, and perceptions around treatment choice and satisfaction. Patients/caregivers also provided their perceptions on treatment choice and satisfaction. Analyses were descriptive. Overall, 55 physicians provided data for 537 pediatric patients, with 111 patients/caregivers also reporting data. The patient population was 63.3% (n = 340) male, and mean ± standard deviation age was 12.6 ± 4.2 years, with 54.0% (n = 290) of patients classified as pediatric (aged ≤ 14 years) and 46.0% (n = 247) adolescent (aged 15-17 years). Patient treatments included topical corticosteroids (TCS; 89.1%, n = 457/513), biologics (12.3%, n = 63/513), oral JAK-is (7.6%, n = 39/513), and immunosuppressants (1.8%, n = 9/513). Physicians reported that they believe better control could be achieved in 64.8% (n = 332) of patients compared with 93.1% (n = 81) of patients self-reporting this. TCS was the most common treatment in pediatric AD management, in agreement with the current guideline recommendation. Overall, most physicians and patients believed that better control could be achieved. However, in mild patients, most patients believed better control could be achieved, while physicians did not. This suggests that views of disease control, and desire for improved disease control, may differ between physicians and patients.
- 18 April 2026
- Published by Springer Nature in Advances in Therapy
- Vol. 43 (7) , 2977-2995
Open AccessTreatment Patterns and Perceptions of Treatment Options in Japanese Pediatric and Adolescent Patients with Atopic Dermatitis
Atopic dermatitis (AD) is a relapsing, chronic inflammatory skin condition characterized by intense itching and eczematous lesions. AD is common in pediatric patients, but treatment options are limited for these patients and data on treatment patterns are scarce. This study aimed to descriptively evaluate treatments used in pediatric AD and physician- and patient-reported perspectives of available options in real-world practice in Japan. Data were drawn from the Adelphi Real World Pediatric and Adolescent AD Disease Specific Programme™, a cross-sectional survey, with retrospective data collection, of physicians and patients in Japan from July to December 2022. Physicians completed patient record forms for their next 3-10 consecutively consulting patients, collecting data on demographics and clinical characteristics, treatment regimens, and perceptions around treatment choice and satisfaction. Patients/caregivers also provided their perceptions on treatment choice and satisfaction. Analyses were descriptive. Overall, 55 physicians provided data for 537 pediatric patients, with 111 patients/caregivers also reporting data. The patient population was 63.3% (n = 340) male, and mean ± standard deviation age was 12.6 ± 4.2 years, with 54.0% (n = 290) of patients classified as pediatric (aged ≤ 14 years) and 46.0% (n = 247) adolescent (aged 15-17 years). Patient treatments included topical corticosteroids (TCS; 89.1%, n = 457/513), biologics (12.3%, n = 63/513), oral JAK-is (7.6%, n = 39/513), and immunosuppressants (1.8%, n = 9/513). Physicians reported that they believe better control could be achieved in 64.8% (n = 332) of patients compared with 93.1% (n = 81) of patients self-reporting this. TCS was the most common treatment in pediatric AD management, in agreement with the current guideline recommendation. Overall, most physicians and patients believed that better control could be achieved. However, in mild patients, most patients believed better control could be achieved, while physicians did not. This suggests that views of disease control, and desire for improved disease control, may differ between physicians and patients.
- Open Access
- 8 January 2026
- Published by Wiley in The Journal of Dermatology
- Vol. 53 (3) , 437-446
Treatment Patterns and Healthcare Utilization on Pediatric Atopic Dermatitis With Allergic Comorbidities: A Japanese Claims‐Based Study
Atopic dermatitis (AD) is a chronic, itchy skin disease that often begins in infancy and may persist into adulthood. The high co‐occurrence of allergic comorbidities (ACMs; asthma, food allergy, and allergic rhinitis) makes it a growing public health concern. However, real‐world data on treatment patterns and the economic burden of AD in children remain sparse. This retrospective observational study aimed to assess the clinical profiles of pediatric patients with AD using data from the JMDC Claims database. Children aged 0–6 years diagnosed with AD between January 2018 and September 2023 were included. A total of 244 316 children with AD (mean age: 3.1 years; 51.3% male) were included. Of these, 17.7% had AD‐only, and 82.3% had AD with ACM. Allergic rhinitis was the most prevalent ACM. Topical corticosteroids were the most prescribed treatment, with 94.0% of patients with ACMs and 85.5% of those with AD‐only receiving them. Potent corticosteroids were more frequently used in the AD with ACM group. Systemic steroids (31.5% vs. 4.8%) and antihistamines (95.5% vs. 56.1%) were used more often in the AD with ACMs group than in the AD‐only group. Patients in the AD with ACM versus AD‐only group had more outpatient visits (11.1/year vs. 6.5/year) and comparable hospitalization frequency, but shorter hospital stays (2.4 vs. 7.7 days per year). Median annual healthcare costs were substantially higher in the AD with ACM group compared to the AD‐only group (139 391 Yen vs. 98 646 Yen), with costs increasing as the number of ACMs increased. Notably, 84.7% of patients with three ACMs incurred annual healthcare costs exceeding 100 000 Yen. These findings highlighted the increased clinical and economic burden associated with the increasing number of ACMs in children with AD, emphasizing the need for more intensive treatment and healthcare resources.
- 8 January 2026
- Published by Wiley in The Journal of Dermatology
- Vol. 53 (3) , 437-446
Open AccessTreatment Patterns and Healthcare Utilization on Pediatric Atopic Dermatitis With Allergic Comorbidities: A Japanese Claims‐Based Study
Atopic dermatitis (AD) is a chronic, itchy skin disease that often begins in infancy and may persist into adulthood. The high co‐occurrence of allergic comorbidities (ACMs; asthma, food allergy, and allergic rhinitis) makes it a growing public health concern. However, real‐world data on treatment patterns and the economic burden of AD in children remain sparse. This retrospective observational study aimed to assess the clinical profiles of pediatric patients with AD using data from the JMDC Claims database. Children aged 0–6 years diagnosed with AD between January 2018 and September 2023 were included. A total of 244 316 children with AD (mean age: 3.1 years; 51.3% male) were included. Of these, 17.7% had AD‐only, and 82.3% had AD with ACM. Allergic rhinitis was the most prevalent ACM. Topical corticosteroids were the most prescribed treatment, with 94.0% of patients with ACMs and 85.5% of those with AD‐only receiving them. Potent corticosteroids were more frequently used in the AD with ACM group. Systemic steroids (31.5% vs. 4.8%) and antihistamines (95.5% vs. 56.1%) were used more often in the AD with ACMs group than in the AD‐only group. Patients in the AD with ACM versus AD‐only group had more outpatient visits (11.1/year vs. 6.5/year) and comparable hospitalization frequency, but shorter hospital stays (2.4 vs. 7.7 days per year). Median annual healthcare costs were substantially higher in the AD with ACM group compared to the AD‐only group (139 391 Yen vs. 98 646 Yen), with costs increasing as the number of ACMs increased. Notably, 84.7% of patients with three ACMs incurred annual healthcare costs exceeding 100 000 Yen. These findings highlighted the increased clinical and economic burden associated with the increasing number of ACMs in children with AD, emphasizing the need for more intensive treatment and healthcare resources.